Precision Psychiatry: A Fireside Chat on Redefining the Treatment of Mental Health Disorders

In honor of National Mental Health Awareness Month, this fireside chat with Mike Hanley (Chief Operating Officer, Alto Neuroscience) will explore groundbreaking advancements that are leading an exciting new era of precision psychiatry. The conversation will focus on Alto’s mission to redefine psychiatry by leveraging individuals’ neurobiology to develop personalized and highly effective medicines. Alto’s biomarker-driven pipeline aims to address specific phenotypes of broader psychiatric diagnoses, with an initial focus on major depressive disorder, bipolar depression, and schizophrenia. By leveraging biomarker-driven trials, advanced analytics, and innovative technologies, the industry can move beyond traditional trial-and-error approaches, redefine psychiatric care and drive meaningful advancements for patients.